Neurogene (NGNE) News Today

Neurogene (NASDAQ:NGNE) Trading 4.5% Higher

Great Point Partners LLC purchased a new position in Neurogene Inc. (NASDAQ:NGNE - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 994,229 shares of the company's stock, valued at approximately $19,268,00

Avidity Partners Management LP purchased a new position in Neurogene Inc. (NASDAQ:NGNE - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 466,243 shares of the company's stock, valued at approx

Robert W. Baird assumed coverage on shares of Neurogene in a research note on Tuesday. They set an "outperform" rating and a $54.00 target price for the company.

Shares of Neurogene Inc. (NASDAQ:NGNE - Get Free Report) have earned an average rating of "Buy" from the six research firms that are presently covering the company, Marketbeat reports. Six investment analysts have rated the stock with a buy recommendation. The average 1-year price target among bro

HC Wainwright reduced their target price on Neurogene from $55.00 to $51.00 and set a "buy" rating on the stock in a report on Monday.

Neurogene Inc. (NASDAQ:NGNE - Free Report) - William Blair raised their Q2 2024 earnings per share estimates for Neurogene in a research note issued on Tuesday, May 7th. William Blair analyst S. Corwin now expects that the company will post earnings per share of ($0.89) for the quarter, up from t

Neurogene Inc. (NASDAQ:NGNE - Free Report) - Investment analysts at William Blair issued their Q1 2025 EPS estimates for shares of Neurogene in a report issued on Tuesday, May 7th. William Blair analyst S. Corwin anticipates that the company will post earnings of ($0.84) per share for the quarter

HC Wainwright reaffirmed a "buy" rating and issued a $55.00 price target on shares of Neurogene in a report on Friday.

Shares of Neurogene Inc. (NASDAQ:NGNE - Get Free Report) have been given an average recommendation of "Buy" by the six brokerages that are presently covering the stock, Marketbeat reports. Six analysts have rated the stock with a buy recommendation. The average 12 month price objective among broke

Neurogene Inc. (NASDAQ:NGNE - Free Report) - Leerink Partnrs issued their Q1 2024 EPS estimates for shares of Neurogene in a note issued to investors on Monday, April 29th. Leerink Partnrs analyst M. Foroohar forecasts that the company will post earnings per share of ($1.19) for the quarter. Leer

Leerink Partnrs reiterated an "outperform" rating on shares of Neurogene in a report on Monday.

SVB Leerink initiated coverage on Neurogene in a report on Monday. They set an "outperform" rating and a $46.00 price target on the stock.

Neurogene Inc. (NASDAQ:NGNE - Free Report) - Equities research analysts at William Blair lowered their Q1 2024 EPS estimates for shares of Neurogene in a report released on Wednesday, April 17th. William Blair analyst S. Corwin now expects that the company will post earnings per share of ($1.38)

Neurogene (NASDAQ:NGNE) Trading Up 3.3%

Neurogene (NASDAQ:NGNE) Sees Unusually-High Trading Volume

Neurogene (NASDAQ:NGNE) Trading Up 5.2%

William Blair assumed coverage on Neurogene in a research report on Thursday. They issued an "outperform" rating and a $61.00 price objective on the stock.

Neurogene Inc. (NASDAQ:NGNE - Free Report) - Equities research analysts at HC Wainwright reduced their Q1 2024 earnings per share (EPS) estimates for shares of Neurogene in a report issued on Tuesday, March 19th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings

Neurogene Inc. (NASDAQ:NGNE - Free Report) - Research analysts at HC Wainwright issued their FY2025 earnings estimates for Neurogene in a research note issued on Tuesday, March 19th. HC Wainwright analyst M. Kapoor forecasts that the company will earn ($4.15) per share for the year. HC Wainwright

HC Wainwright lifted their price objective on shares of Neurogene from $45.00 to $55.00 and gave the stock a "buy" rating in a research report on Tuesday.

HC Wainwright reiterated a "buy" rating and set a $45.00 price objective on shares of Neurogene in a research report on Tuesday.